drugset / Trial / NCT06070610
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
NaCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to investigate the induction effect of multiple oral doses of BI 1015550 on the pharmacokinetics of nintedanib or pirfenidone.
Timeline
- Start
- 2023-11-08
- Primary completion
- 2023-12-14
- Completion
- 2023-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nerandomilast | Small molecule | 18 mg | Oral |
| Subject | Nintedanib | Small molecule | 100 mg | — |
| Subject | Pirfenidone | Small molecule | 267 mg | — |
Indications
No indication recorded.